Clinical trial · Observational
FET-PET/MRI Based Treatment Planning for Glioblastoma Multiforme in Post-Surgical Patients (FET-TREAT)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Glioblastoma multiforme (GBM) represent the most common primary brain malignancy and prognosis remains poor. The most common subtype is glioblastoma which has a 5-year survival rate of approximately 5%. Despite advances in MRI techniques, accurately determining total extent of tumor remains a challenge. The result is incomplete treatment resulting in reduced survival or overtreatment resulting in avoidable treatment related morbidity. A more accurate means of assessing tumor extent is needed to guide management to improve patient survival and quality of life.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Glioblastoma Multiforme | Glioblastoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| FET-PET/MRI | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Post-Operative GBM Positron Emission Tomography/Magnetic Resonance Imaging (PET/MRI)
- description
- 0-(2-18F-Fluoroethyl)-L-Tyrosine (FET) PET/MRI for planning of radiation therapy of post-operative glioblastoma multiforme patients
- interventionNames
- Diagnostic Test: FET-PET/MRI
Primary outcomes (1)
- measure
- Difference in radiation treatment volume as determined by FET-PET/MRI compared to standard of care MRI.
- timeFrame
- 12 months
- description
- Volume difference measured in cubic centimetres
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: Each participant must meet all of the following inclusion criteria to participate in this study: * ≥ 18 years of age * Diagnosis of glioblastoma multiforme * Post-maximally safe surgical resection * No prior radiation or systemic treatment for high grade glioma * Able to tolerate PET/MRI scan with intravenous contrast * Willing to provide informed consent Exclusion Criteria: All participants meeting any of the following exclusion criteria at baseline screening will be excluded from participation in this study: * MRI contraindication * Creatinine clearance \< 30mL/min * Inability to lie still for 60 minutes * Gadolinium allergy * Positive pregnancy test * Breastfeeding * Patient unable to follow the protocol for any reason
References
Publications (0)
Data not yet available